Physician profile
Nehal Patel
NPI 1285840462
$2,705.22
in general payments reported to CMS, 2019-2025
21 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $36.32 · 2021: $82.34 · 2022: $229 · 2023: $708 · 2024: $738 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,971.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $502.47 | 2019-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $235.41 | 2022-2023 | Jesduvroq |
| Vifor Pharma, INC. | $228.25 | 2019-2024 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $222.65 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $197.90 | 2023 | Tarpeyo |
| Lilly USA, LLC | $186.58 | 2022-2025 | Jardiance |
| Ardelyx, INC. | $175.62 | 2023-2025 | Ibsrela |
| Amgen INC. | $146.44 | 2019-2024 | Tavneos, Krystexxa |
| Mallinckrodt Hospital Products INC. | $142.69 | 2024 | Terlivaz |
| Baxter Healthcare | $116.88 | 2019 | |
| Novo Nordisk INC | $105.96 | 2024-2025 | Rybelsus, Ozempic |
| Horizon Therapeutics Plc | $97.46 | 2021-2023 | Krystexxa |
| Akebia Therapeutics INC | $73.33 | 2020-2024 | Auryxia, Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.61 | 2023-2025 | Jardiance |
| Insulet Corporation | $46.55 | 2025 | Omnipod |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $44.93 | 2024 | Lupkynis |
| Chiesi USA, INC. | $34.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $23.43 | 2022 | |
| Esperion Therapeutics, INC. | $19.09 | 2025 | Nexletol |
| Astellas Pharma US INC | $18.89 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $16.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nehal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.